Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer L Taylor

Showing results (11-20 of 227) with videos related to

Pageof 23
Sort By:
Journal of Intensive Care Medicine|November 11, 2006
Critical care perspective on immunotherapy in lung transplantationJennifer L Taylor, Scott M Palmer
The Lancet. Respiratory Medicine|June 3, 2026
Beyond efficacy: registries, equity, and outcomes in the ETI eraJonathan H Rayment, Jennifer L Taylor
Therapeutic Advances in Respiratory Disease|April 28, 2019
The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapySherstin T Lommatzsch, Jennifer L Taylor-Cousar
The European Respiratory Journal|November 14, 2024
Until it's done for everyone: the role of CFTR modulator label expansionClemente J Britto, Jennifer L Taylor-Cousar
Current Opinion in Pulmonary Medicine|August 22, 2021
Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challengesPeter J Barry, Jennifer L Taylor-Cousar
Expert Review of Respiratory Medicine|November 30, 2020
Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic FibrosisPeter G Middleton, Jennifer L Taylor-Cousar
The Lancet. Respiratory Medicine|August 16, 2024
Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosisKatherine Odem-Davis, Jennifer L Taylor-Cousar
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 2, 2017
Let's talk about sex: Behaviors, experience and health care utilization in young women with CFSonya L Heltshe, Jennifer L Taylor-Cousar
The Lancet. Respiratory Medicine|September 26, 2024
Reflections 5 years on from the approval of ETI therapyPeter G Middleton, Jennifer L Taylor-Cousar
Clinics in Chest Medicine|November 7, 2022
Cystic Fibrosis in the Era of Highly Effective CFTR ModulatorsClemente J Britto, Jennifer L Taylor-Cousar
Pageof 23

Showing results (11-20 of 227) with videos related to

Sort By:
Pageof 23
Journal of Intensive Care Medicine|November 11, 2006
Critical care perspective on immunotherapy in lung transplantationJennifer L Taylor, Scott M Palmer
The Lancet. Respiratory Medicine|June 3, 2026
Beyond efficacy: registries, equity, and outcomes in the ETI eraJonathan H Rayment, Jennifer L Taylor
Therapeutic Advances in Respiratory Disease|April 28, 2019
The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapySherstin T Lommatzsch, Jennifer L Taylor-Cousar
The European Respiratory Journal|November 14, 2024
Until it's done for everyone: the role of CFTR modulator label expansionClemente J Britto, Jennifer L Taylor-Cousar
Current Opinion in Pulmonary Medicine|August 22, 2021
Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challengesPeter J Barry, Jennifer L Taylor-Cousar
Expert Review of Respiratory Medicine|November 30, 2020
Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic FibrosisPeter G Middleton, Jennifer L Taylor-Cousar
The Lancet. Respiratory Medicine|August 16, 2024
Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosisKatherine Odem-Davis, Jennifer L Taylor-Cousar
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 2, 2017
Let's talk about sex: Behaviors, experience and health care utilization in young women with CFSonya L Heltshe, Jennifer L Taylor-Cousar
The Lancet. Respiratory Medicine|September 26, 2024
Reflections 5 years on from the approval of ETI therapyPeter G Middleton, Jennifer L Taylor-Cousar
Clinics in Chest Medicine|November 7, 2022
Cystic Fibrosis in the Era of Highly Effective CFTR ModulatorsClemente J Britto, Jennifer L Taylor-Cousar
Pageof 23